PAION’s Novel Sedative/Anaesthetic CNS 7056 Meets Target Profile in Human Proof of Concept Study

AACHEN, Germany & CAMBRIDGE, England--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) today reports the first human data of its intravenous sedative/anaesthetic CNS 7056. The Phase I proof of concept study compared intravenous CNS 7056 to placebo and a standard dose of midazolam, the current gold standard for procedural sedation. The anticipated favourable profile was observed and no safety issues were raised. Volunteers treated with increasing doses of CNS 7056 were successfully sedated at the higher dose cohorts as expected and recovered to full consciousness rapidly.

Back to news